Flow Cytometric Assays For CAR T Cell Manufacturing And Patient Monitoring Involving Specific CAR Detection Reagents

By Marsilius Mues, Stefanie Biedermann, Monika Winkels, Katrin Lange, Laura Stiem, Eva Janz, Michaela Niemöller, Desiré Missing, Nadine Borgelt, Anja Brauchle, Tatjana Holzer, Christian Dose, Christiane Siewert, and Anne Richter, Miltenyi Biotec B.V. & Co. KG

Unprecedented efficacy in targeting cancer has been demonstrated with CAR T cell therapy. However, the CAR T cell manufacturing process is still highly complex and has extensive demands on personnel and infrastructure. The necessary QC procedures and any accompanying CAR T cell phenotyping efforts require robust and reliable assays. Therefore, to streamline the assessment of CAR T cells during manufacturing and patient monitoring, a set of flow cytometric assays prepared from recombinant antibodies along with CAR detection reagents was established. These assays were complemented by stabilized pre-formulated cocktails and additional tools for automated data acquisition and analysis, to achieve the highest level of standardization, reproducibility, and convenience.

Learn about these elaborate flow assays specifically designed for CAR T cells that provide a robust assessment of cell manufacturing and patient immunomonitoring. This will help with establishing complex individualized therapies and will enable us to better understand the phenotypic changes occurring throughout the lifetime of a CAR T cell.